GW Pharmaceuticals (GWPH) saw its stock price fall sharply on the publication of its recent results. This may have been due more to stock manipulation by a few substantial stock owners rather than fundamentals. Analysts remained positive on the stock.
As my recent article detailed, the company has a positive earnings growth ahead and a strong pipeline of new products and new treatments for existing products. It has the cash reserves to continue to progress forward strongly. Revenue for its "epidiolex" drug for TSC (tuberous sclerosis complex) will now start to kick in